• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症恶病质的营养挑战。

Nutrition challenges of cancer cachexia.

机构信息

Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.

出版信息

JPEN J Parenter Enteral Nutr. 2021 Nov;45(S2):16-25. doi: 10.1002/jpen.2287.

DOI:10.1002/jpen.2287
PMID:34897740
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8756772/
Abstract

Cancer cachexia, or progressive weight loss, often despite adequate nutrition contributes greatly to cancer morbidity and mortality. Cachexia is metabolically distinct from starvation or protein malnutrition, although many patients with cancer and cachexia exhibit lowered appetite and food consumption. Tumors affect neural mechanisms that regulate appetite and energy expenditure, while promoting wasting of peripheral tissues via catabolism of cardiac and skeletal muscle, adipose, and bone. These multimodal actions of tumors on the host suggest a need for multimodal interventions. However, multiple recent consensus guidelines for management of cancer cachexia differ in treatment recommendations, highlighting the lack of effective, available therapies. Challenges to defining appropriate nutrition or other interventions for cancer cachexia include lack of consensus on definitions, low strength of evidence from clinical trials, and a scarcity of robust, rigorous, and mechanistic studies. However, efforts to diagnose, stage, and monitor cachexia are increasing along with clinical trial activity. Furthermore, preclinical models for cancer cachexia are growing more sophisticated, encompassing a greater number of tumor types in organ-appropriate contexts and for metastatic disease to model the clinical condition more accurately. It is expected that continued growth, investment, and coordination of research in this topic will ultimately yield robust biomarkers, clinically useful classification and staging algorithms, targetable pathways, pivotal clinical trials, and ultimately, cures. Here, we provide an overview of the clinical and scientific knowledge and its limitations around cancer cachexia.

摘要

癌症恶病质,或进行性体重下降,尽管有充足的营养,也常常极大地导致癌症发病率和死亡率上升。恶病质与饥饿或蛋白质营养不良不同,尽管许多癌症恶病质患者表现出食欲下降和食物摄入减少。肿瘤影响调节食欲和能量消耗的神经机制,同时通过心脏和骨骼肌肉、脂肪和骨的分解代谢促进外周组织的消耗。肿瘤对宿主的这些多模式作用表明需要多模式干预。然而,最近关于癌症恶病质管理的多项共识指南在治疗建议上存在差异,突出了缺乏有效、可用的治疗方法。癌症恶病质适当营养或其他干预措施的定义存在挑战,包括对定义缺乏共识、临床试验证据强度低,以及缺乏强有力、严格和机制研究。然而,诊断、分期和监测恶病质的努力正在增加,同时临床试验活动也在增加。此外,癌症恶病质的临床前模型越来越复杂,在适当的器官背景下包含更多的肿瘤类型,并用于转移性疾病,以更准确地模拟临床状况。预计在这个课题的研究方面的持续增长、投资和协调将最终产生强大的生物标志物、临床上有用的分类和分期算法、可靶向的途径、关键临床试验,最终实现治愈。在这里,我们概述了癌症恶病质的临床和科学知识及其局限性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c191/8756772/c97e4510baa4/nihms-1750191-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c191/8756772/c97e4510baa4/nihms-1750191-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c191/8756772/c97e4510baa4/nihms-1750191-f0001.jpg

相似文献

1
Nutrition challenges of cancer cachexia.癌症恶病质的营养挑战。
JPEN J Parenter Enteral Nutr. 2021 Nov;45(S2):16-25. doi: 10.1002/jpen.2287.
2
Cancer cachexia: an overview of diagnostic criteria and therapeutic approaches for the accredited practicing dietitian.癌症恶病质:经认证的执业营养师的诊断标准和治疗方法概述。
J Hum Nutr Diet. 2021 Feb;34(1):243-254. doi: 10.1111/jhn.12811. Epub 2020 Oct 10.
3
[Recent development in research and management of cancer anorexia-cachexia syndrome].[癌症恶病质综合征的研究与管理新进展]
Gan To Kagaku Ryoho. 2005 Jun;32(6):743-9.
4
Nutritional support in multimodal therapy for cancer cachexia.癌症恶病质多模式治疗中的营养支持
Support Care Cancer. 2008 May;16(5):447-51. doi: 10.1007/s00520-007-0388-7. Epub 2008 Jan 15.
5
Treatment of unintentional weight loss in patients with cancer.癌症患者非故意体重减轻的治疗。
Nutr Clin Pract. 2005 Aug;20(4):400-10. doi: 10.1177/0115426505020004400.
6
What we have learned about cachexia in gastrointestinal cancer.我们对胃肠道癌症恶病质的了解。
Dig Dis. 2003;21(3):198-213. doi: 10.1159/000073337.
7
New strategies to overcome cancer cachexia: from molecular mechanisms to the 'Parallel Pathway'.克服癌症恶病质的新策略:从分子机制到“平行途径”
Asia Pac J Clin Nutr. 2008;17 Suppl 1:387-90.
8
SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023).SEOM 癌症恶病质厌食症综合征临床指南(2023 年)。
Clin Transl Oncol. 2024 Nov;26(11):2866-2876. doi: 10.1007/s12094-024-03502-8. Epub 2024 Jun 1.
9
Cancer cachexia: it's time for more clinical trials.癌症恶病质:是时候开展更多临床试验了。
Ann Surg Oncol. 2007 Feb;14(2):276-85. doi: 10.1245/s10434-006-9179-5. Epub 2006 Nov 9.
10
Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions.癌症恶病质的研究进展:受影响器官、介质和药物干预的交叉点。
Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188359. doi: 10.1016/j.bbcan.2020.188359. Epub 2020 Mar 25.

引用本文的文献

1
Intramuscular CMT-167 Tumors Produce a Mild Cachexia Phenotype in C57BL/6J Mice.肌肉注射CMT-167肿瘤在C57BL/6J小鼠中产生轻度恶病质表型。
JCSM Commun. 2025 Jan-Jun;8(1). doi: 10.1002/rco2.117. Epub 2025 Feb 6.
2
Immunotherapy of small cell lung cancer based on prognostic nutritional index.基于预后营养指数的小细胞肺癌免疫治疗
Front Immunol. 2025 May 26;16:1560241. doi: 10.3389/fimmu.2025.1560241. eCollection 2025.
3
The Impact of Nutritional Support on Outcomes of Lung Cancer Surgery-Narrative Review.营养支持对肺癌手术结局的影响——叙述性综述

本文引用的文献

1
Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multi-cohort analysis.癌症恶病质的诊断标准:国际多队列分析表明,减少食物摄入和炎症可预测体重减轻和生存。
J Cachexia Sarcopenia Muscle. 2021 Oct;12(5):1189-1202. doi: 10.1002/jcsm.12756. Epub 2021 Aug 27.
2
Early-Onset Physical Inactivity and Metabolic Dysfunction in Tumor-bearing Mice Is Associated with Accelerated Cachexia.荷瘤小鼠早期体力活动不足与代谢功能障碍相关,并加速恶病质的发生。
Med Sci Sports Exerc. 2022 Jan 1;54(1):77-88. doi: 10.1249/MSS.0000000000002772.
3
Corrigendum to <'New cancer cachexia staging system for use in clinical practice' [Nutrition 90 (2021) 111271]>.
J Clin Med. 2025 May 5;14(9):3197. doi: 10.3390/jcm14093197.
4
Artificial Intelligence in the Management of Malnutrition in Cancer Patients: A Systematic Review.人工智能在癌症患者营养不良管理中的应用:一项系统综述。
Adv Nutr. 2025 May 5:100438. doi: 10.1016/j.advnut.2025.100438.
5
Impact of Malnutrition on the Length of Stay for Hospitalized Chimeric Antigen Receptor T-cell (CAR-T) Therapy Patients in the United States (2020).营养不良对美国住院嵌合抗原受体T细胞(CAR-T)治疗患者住院时间的影响(2020年)
Cureus. 2024 Oct 25;16(10):e72400. doi: 10.7759/cureus.72400. eCollection 2024 Oct.
6
Comparison of nasojejunal nutrition and intravenous nutrition supplementation in patients with upper gastrointestinal tract strictures and analysis of risk factors for malnutrition.比较上消化道狭窄患者经鼻空肠营养与静脉营养补充的效果及营养不良的危险因素分析。
Medicine (Baltimore). 2024 Jul 5;103(27):e38820. doi: 10.1097/MD.0000000000038820.
7
Doxorubicin causes cachexia, sarcopenia, and frailty characteristics in mice.多柔比星导致小鼠恶病质、肌肉减少症和虚弱特征。
PLoS One. 2024 Apr 22;19(4):e0301379. doi: 10.1371/journal.pone.0301379. eCollection 2024.
8
Molecular Mechanisms of Cachexia: A Review.恶病质的分子机制:综述。
Cells. 2024 Jan 29;13(3):252. doi: 10.3390/cells13030252.
9
Nutritional Assessment Tools for Patients with Cancer: A Narrative Review.癌症患者的营养评估工具:一项叙述性综述。
Curr Med Sci. 2024 Feb;44(1):71-80. doi: 10.1007/s11596-023-2808-4. Epub 2024 Jan 30.
10
Exploring the Therapeutic Potential of Ethyl 3-Hydroxybutyrate in Alleviating Skeletal Muscle Wasting in Cancer Cachexia.探索3-羟基丁酸乙酯在减轻癌症恶病质骨骼肌萎缩方面的治疗潜力。
Biomolecules. 2023 Aug 30;13(9):1330. doi: 10.3390/biom13091330.
《“用于临床实践的新癌症恶病质分期系统”[《营养》90(2021)111271]》勘误
Nutrition. 2021 Oct;90:111410. doi: 10.1016/j.nut.2021.111410. Epub 2021 Aug 3.
4
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines.成人癌症恶病质:ESMO 临床实践指南。
ESMO Open. 2021 Jun;6(3):100092. doi: 10.1016/j.esmoop.2021.100092.
5
Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia.肿瘤来源的 IL-6 和肿瘤、脂肪和肌肉之间的转信号介导胰腺癌恶病质。
J Exp Med. 2021 Jun 7;218(6). doi: 10.1084/jem.20190450.
6
Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia.脂联素 2 在胰腺癌恶病质期间介导食欲抑制。
Nat Commun. 2021 Apr 6;12(1):2057. doi: 10.1038/s41467-021-22361-3.
7
Cancer-induced Cardiac Atrophy Adversely Affects Myocardial Redox State and Mitochondrial Oxidative Characteristics.癌症诱导的心脏萎缩对心肌氧化还原状态和线粒体氧化特性产生不利影响。
JCSM Rapid Commun. 2021 Jan-Jun;4(1):3-15. doi: 10.1002/rco2.18. Epub 2020 Aug 7.
8
Reduced rDNA transcription diminishes skeletal muscle ribosomal capacity and protein synthesis in cancer cachexia.rDNA 转录减少会降低癌症恶病质患者骨骼肌的核糖体容量和蛋白质合成。
FASEB J. 2021 Feb;35(2):e21335. doi: 10.1096/fj.202002257R.
9
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial.贝马鲁单抗对比安慰剂对 2 型糖尿病合并肥胖成人患者体脂量的影响:一项 2 期随机临床试验。
JAMA Netw Open. 2021 Jan 4;4(1):e2033457. doi: 10.1001/jamanetworkopen.2020.33457.
10
Diverging metabolic programmes and behaviours during states of starvation, protein malnutrition, and cachexia.在饥饿、蛋白质营养不良和恶病质状态下,代谢方案和行为出现分歧。
J Cachexia Sarcopenia Muscle. 2020 Dec;11(6):1429-1446. doi: 10.1002/jcsm.12630. Epub 2020 Sep 28.